A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...
A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.
(UroToday.com) The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session and a presentation by Molly Wynveen discussing survival in Veterans with metastatic ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen deprivation therapy cuts the risk of death by 40% over 8 years, according to ...
Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...
For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...